PPARA and depressive symptom measurement: Figure 7A shows that pre-treatment with PPARα-shRNA significantly abolished the antidepressant-like effects of chiglitazar in the CUMS model of depression, as the (CUMS + chiglitazar + PPARα-shRNA)-treated mice displayed significantly higher immobility in the FST [ANOVA: F(6, 63) = 23.846, P < 0.01] and TST [ANOVA: F(6, 63) = 25.141, P < 0.01] as well as lower sucrose preference [ANOVA: F(6, 63) = 27.596, P < 0.01] than both the (CUMS + chiglitazar)-treated and (CUMS + chiglitazar + Control-shRNA)-treated mice (n = 10, P < 0.01).